Your body can make [DHA | docosahexaenoic acid — the primary omega-3 fat in brain tissue, the retina, and cell membranes throughout the nervous system] from shorter omega-3 fats, but the last elongation step is rate-limiting. ELOVL2 (elongation of very long chain fatty acids 2) is the enzyme responsible for converting DPA into the final DHA product. Variants at the ELOVL2 locus¹¹ Variants at the ELOVL2 locus
rs3734398 is a 3′ UTR variant at chromosome 6p24.2 that influences ELOVL2 expression and enzyme efficiency substantially change how much DHA reaches the bloodstream — regardless of how much fish you eat.

ELOVL2 has a second claim to fame: its promoter methylation is the strongest known epigenetic clock signal in the human genome. DNA methylation at this locus²² DNA methylation at this locus
ELOVL2 methylation accumulates linearly from birth to old age, explaining 70% of the variance in epigenetic age across multiple tissues increases with every year of life, a finding replicated in hundreds of age-estimation studies. The rs3734398 variant sits at the junction of two of the most important health-related biological processes: DHA metabolism and epigenetic aging.

The Mechanism

The omega-3 synthesis pathway runs: ALA → EPA → DPA → DHA. ELOVL2 catalyzes the penultimate elongation step (DPA → 24:5n-3), and the downstream desaturase then produces DHA via 24:6n-3. The rs3734398 C allele alters expression of the ELOVL2 3′ UTR, modifying enzyme activity in a way that partially impairs the DPA-to-DHA conversion³³ partially impairs the DPA-to-DHA conversion
carriers accumulate more DPA substrate and produce less DHA product, explaining the simultaneous elevation of EPA+DPA and reduction of DHA observed in GWAS. This is a functional bottleneck: the upstream elongation steps are not affected, so EPA and DPA build up while DHA output falls.

Importantly, the C allele also appears to be associated with higher ELOVL2 mRNA expression⁴⁴ higher ELOVL2 mRNA expression
Dai et al. (2019) found CC genotype was associated with significantly increased ELOVL2 mRNA levels in melanoma tissue, suggesting the variant may produce a qualitatively different enzyme or alter splicing rather than simply reducing transcription. The precise molecular mechanism at the 3′ UTR remains under study.

The Evidence

The landmark CHARGE Consortium GWAS meta-analysis⁵⁵ CHARGE Consortium GWAS meta-analysis
Lemaitre RN et al. Genetic loci associated with plasma phospholipid n-3 fatty acids. PLoS Genet, 2011 across 8,866 individuals of European ancestry established the ELOVL2 locus as one of only three genome-wide significant loci for plasma phospholipid omega-3 fatty acids. The C allele was associated with higher EPA (p=2×10⁻¹²) and DPA (p=1×10⁻⁴³) but lower DHA (p=1×10⁻¹⁵), consistent across all ancestry groups with sufficient C-allele polymorphism.

The MARINA randomized trial by Alsaleh et al.⁶⁶ Alsaleh et al.
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr, 2014 (n=310, six months, up to 1.8 g/day EPA+DHA) showed that C-allele carriers had significantly lower plasma DHA at baseline (p=0.021) but responded more robustly to supplementation: at 1.8 g/day, C-allele carriers gained 25.7% more EPA (p=0.003) and 8.7% more DHA (p=0.016) relative to TT homozygotes. The dose-response was significant only at the highest dose tested.

In a separate melanoma survival cohort, the C allele was associated with lower all-cause melanoma mortality⁷⁷ C allele was associated with lower all-cause melanoma mortality
Dai W et al. Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival. Int J Cancer, 2019 (HR=0.66, 95% CI 0.51–0.84), an association the authors attributed to ELOVL2-mediated effects on PUFA composition and cellular membrane integrity. The CC genotype was associated with increased ELOVL2 mRNA expression in tumor tissue, suggesting complex genotype-expression relationships that extend beyond simple DHA reduction.

Practical Actions

For C-allele carriers (CT or CC), the core implication is that dietary conversion of EPA to DHA is less efficient than average. Plant-based omega-3 sources (ALA from flax, chia, walnuts) are even less useful than usual, since they must traverse the entire conversion pathway including this bottleneck. Preformed EPA and DHA from marine or algae-based sources bypass the impaired elongation step and directly raise plasma DHA. At the 1.8 g/day dose used in MARINA, C-allele carriers showed a greater absolute response than TT homozygotes, so the supplement recommendation has direct evidence, not just theoretical support.

TT homozygotes have the most efficient DHA synthesis from DPA and can maintain higher plasma DHA levels on habitual diet. They still benefit from dietary EPA/DHA sources, but the urgency for supplementation is lower.

Interactions

rs3734398 sits in the same biological pathway as the FADS1/FADS2 desaturase variants (rs174547 and related), which operate earlier in the omega-3 synthesis chain (ALA→EPA, EPA→DPA). A person carrying both FADS1/FADS2 risk variants AND the ELOVL2 C allele faces impairment at multiple sequential steps of DHA synthesis, making the need for preformed marine EPA/DHA substantially greater than either variant alone. rs2236212 is in near-complete linkage disequilibrium with rs3734398 (r²=0.966) and is the same functional signal; users who have data on one effectively have data on both.

Your liver is a lipid logistics hub. Every gram of fat synthesized from excess carbohydrate, every fatty acid rescued from circulation, every dietary fat re-exported after absorption — all of it leaves the liver packaged into VLDL particles¹¹ VLDL particles
Very-low-density lipoprotein: triglyceride-rich particles assembled in the liver and secreted into blood, where they deliver fat to peripheral tissues. The enzyme responsible for loading triglycerides into those particles is MTTP — microsomal triglyceride transfer protein²² MTTP — microsomal triglyceride transfer protein
MTTP transfers triglycerides, phospholipids, and cholesteryl esters onto nascent apolipoprotein B during VLDL assembly in the liver and chylomicron assembly in the intestine. Without functional MTTP, VLDL cannot be assembled, triglycerides accumulate in hepatocytes, and plasma lipid levels fall sharply — the phenotype of abetalipoproteinemia, a rare recessive disorder caused by null MTTP mutations.

The I128T variant (rs3816873) substitutes isoleucine for threonine at position 128 of the MTTP protein. It is common — the Thr128 (C) allele occurs in about 25% of Europeans and 34% of South Asians — yet it was classified as benign for years, its metabolic effects dismissed as too modest to matter. That view has changed.

The Mechanism

Isoleucine at position 128³³ Isoleucine at position 128
A nonpolar, branched-chain amino acid embedded in the hydrophobic core of the MTTP N-terminal domain sits in a region of MTTP critical for its lipid-transfer scaffold. The Ile→Thr substitution⁴⁴ Ile→Thr substitution
Threonine is polar and hydroxyl-bearing; replacing a hydrophobic residue with a polar one at this position likely alters the protein's local conformational dynamics changes the physicochemical character of this site — polar threonine where non-polar isoleucine once held structure. This does not abolish MTTP activity (as null mutations do in abetalipoproteinemia), but it appears to subtly reconfigure how efficiently MTTP loads triglycerides onto nascent VLDL particles. A 2023 study in 489,000+ participants concluded the I128T variant is "neither a classic loss nor gain of function allele," pointing to a more nuanced alteration of MTP lipid-transfer dynamics that simultaneously reduces hepatic fat retention and plasma lipid levels.

The Evidence

The strongest evidence comes from a large biobank study⁵⁵ large biobank study
Schneider et al. 2023, Penn Medicine Biobank (n=37,960) and UK Biobank (n=451,444), examining 24 MTTP missense variants. Carriers of the Thr128 (C) allele showed reduced hepatic steatosis on imaging, fewer biopsy-proven steatosis cases, and lower plasma LDL-cholesterol and apoB concentrations (all p<0.001). The scale of this study makes confounding unlikely.

Smaller studies give a more complex picture. A 2011 Iranian case-control study⁶⁶ 2011 Iranian case-control study
Hashemi et al., 83 NAFLD cases vs. 93 controls, DNA Cell Biol found the CT genotype had an OR of 2.467 (95% CI 1.253–4.854) for NAFLD — a risk direction opposite to the biobank data. However, a 2020 meta-analysis of 10 case-control studies⁷⁷ 2020 meta-analysis of 10 case-control studies
Tan et al., 1,388 NAFLD cases and 1,690 controls, Saudi J Gastroenterol found no significant overall association (OR 1.23, 95% CI 0.76–2.01, p=0.398), implying the small-study positive findings likely reflect population stratification or underpowering. In the context of viral hepatitis, the variant showed a strong interaction effect: Prata et al. 2022⁸⁸ Prata et al. 2022
236 chronic hepatitis C patients, Clinics São Paulo found the I128T allele combined with HCV genotype 3 produced an 8.5-fold elevated steatosis risk — a clinically important gene-virus interaction.

For plasma lipids, evidence from a large German cohort⁹⁹ large German cohort
Böhme et al. 2008, KORA study, n=7,582, Mol Genet Metab found MTTP variants modulated lipid homeostasis, with sex-specific effects. For Korean patients with alcoholic liver disease, the wild-type Ile128 (T allele)¹⁰¹⁰ wild-type Ile128 (T allele)
Jun et al. 2009, Eur J Gastroenterol Hepatol was more prevalent in those with fatty liver, and I/I carriers showed significantly elevated ALT — consistent with the C allele (Thr128) being protective in the context of alcohol-related hepatic stress.

Practical Actions

The Thr128 C allele is associated with modestly better lipid export efficiency and reduced hepatic fat accumulation at population scale. Homozygous C;C carriers may have a metabolic advantage in terms of VLDL assembly, translating to lower LDL-C and apoB, which directly reduces cardiovascular disease risk.

Wild-type T;T homozygotes carry the ancestrally common form (Ile128) and appear to have a slightly less efficient lipid export phenotype — their hepatic fat risk is not dramatic but warrants awareness, particularly in the context of high dietary saturated fat intake or alcohol use, both of which impose hepatic triglyceride loading that depends on efficient VLDL secretion via MTTP.

Heterozygous C;T carriers fall between these two extremes, with one copy of the efficiency-altering allele.

Interactions

The most clinically documented interaction is with HCV genotype 3 infection: I128T carriers with this viral strain show dramatically elevated hepatic steatosis risk (OR ~8.5), suggesting the variant's effect on MTTP function is exacerbated by HCV-driven lipid dysregulation. This is a gene-virus interaction rather than a gene-gene interaction in the traditional sense.

For gene-gene interactions, MTTP function interacts with APOE genotype (which governs apolipoprotein B receptor-mediated clearance), PCSK9 variants (which modulate LDL receptor density), and PNPLA3 rs738409 (a well-replicated NAFLD risk variant in a different pathway — hepatic triglyceride hydrolysis). T;T carriers who also carry PNPLA3 GG or APOE ε4 may face compounding hepatic lipid stress from impaired export (MTTP) and impaired hydrolysis (PNPLA3) or elevated apoB production (APOE).

Mitochondrial complex I (NADH:ubiquinone oxidoreductase¹¹ NADH:ubiquinone oxidoreductase
The largest enzyme in the mitochondrial respiratory chain, comprising 45 subunits, 14 of which form the catalytic core. It transfers electrons from NADH to ubiquinone, pumping protons to drive ATP synthesis) is the cell's primary engine for converting food into energy. The NDUFS4 subunit is a nuclear-encoded accessory subunit²² nuclear-encoded accessory subunit
NDUFS4 is encoded in the nuclear genome and imported into the mitochondrial matrix; it stabilizes the final assembly of the complex I holocomplex and carries a cAMP-dependent phosphorylation site that regulates enzyme activation required for complete complex I assembly and activation. The c.462delA frameshift — a single adenine deletion at position 462 in the coding sequence — disrupts the reading frame at codon 154, producing a truncated protein (p.Lys154fs) that lacks the phosphorylation site essential for complex I activation.

Among Ashkenazi Jewish families, this variant has been identified as a founder mutation³³ founder mutation
A mutation present in high frequency in a specific population due to descent from a small number of founders who carried the variant; the AJ population has experienced several well-characterized founder effects for recessive disease alleles with a carrier frequency of approximately 1 in 1,000. For most carriers, the other copy of NDUFS4 is intact and complex I function is entirely normal. The risk materializes only when both parents are carriers, giving each child a 25% chance of inheriting two deletion alleles and developing Leigh syndrome.

The Mechanism

The c.462delA deletion shifts the reading frame after codon 154, replacing the final 22 amino acids of NDUFS4 with a novel sequence before encountering a premature stop codon. The resulting truncated protein cannot serve its normal role in complex I holocomplex stabilization⁴⁴ complex I holocomplex stabilization
NDUFS4 is incorporated in one of the last steps of complex I assembly. Without functional NDUFS4, the 550-kilodalton membrane-arm complex assembles but remains unstable and is present at sharply reduced levels. The critical phosphorylation site for cAMP-dependent kinase activation is also absent, further impairing the enzyme's ability to respond to cellular energy signals.

Homozygous loss of NDUFS4 therefore creates a state of severe mitochondrial energy deficiency. Neurons — which depend almost entirely on oxidative phosphorylation — are the most vulnerable cell type. In the Ndufs4 knockout mouse model, glutamatergic neurons mediate most of the motor and respiratory phenotype⁵⁵ glutamatergic neurons mediate most of the motor and respiratory phenotype
Single-cell studies show Vglut2-expressing glutamatergic neurons in the brainstem die earliest; GABAergic neurons contribute later through inflammation and epilepsy, while activated microglia drive a secondary neuroinflammatory cascade involving NLRP3 inflammasome and IL-6⁶⁶ NLRP3 inflammasome and IL-6
Elevated NLRP3 and IL-6 pro-inflammatory pathways were confirmed in NDUFS4-mutant iPSC-derived brain organoids and postmortem Leigh syndrome tissue from human patients that amplifies neuronal death.

The Evidence

The clinical significance of biallelic NDUFS4 loss is unambiguous. Leigh syndrome (subacute necrotizing encephalomyelopathy) caused by NDUFS4 mutations presents in infancy or early childhood with developmental regression, hypotonia, feeding difficulties, respiratory failure, and characteristic bilateral symmetric lesions in the basal ganglia and brainstem on MRI. The course is typically progressive and often fatal within the first years of life⁷⁷ often fatal within the first years of life
Published case series document death from respiratory failure, usually before age 5, in most NDUFS4-null children; some survive longer with intensive supportive care.

Anderson et al. 2008⁸⁸ Anderson et al. 2008
Journal of Inherited Metabolic Disease, December 2008 (PMID 19107570) identified c.462delA as the causal mutation in three affected children from a non-consanguineous Ashkenazi Jewish family. Screening of 5,000 healthy AJ individuals revealed a carrier frequency of approximately 1 in 1,000, leading the authors to recommend that this variant should be evaluated in all AJ patients presenting with Leigh syndrome before proceeding to more extensive enzyme studies.

Leshinsky-Silver et al. 2009⁹⁹ Leshinsky-Silver et al. 2009
Molecular Genetics and Metabolism, July 2009 (PMID 19364667) confirmed p.Lys154fs in a second patient — a compound heterozygote carrying the AJ founder allele alongside a novel NDUFS4 missense — with Leigh syndrome showing predominant brainstem involvement and fatal outcome in early childhood. Together these reports establish the biological mechanism, the Ashkenazi Jewish population risk, and the clinical phenotype.

Practical Actions

For confirmed carriers (DI genotype), the finding has no impact on personal health — complex I activity is entirely normal with one functional allele. The clinical relevance is reproductive: if a carrier has a child with a partner who is also a carrier, each pregnancy has a 25% risk of Leigh syndrome.

Carrier screening for the Ashkenazi Jewish population panel should include NDUFS4 c.462delA. Several expanded carrier screening programs include it explicitly. For carriers planning a family, preconception genetic counseling can guide decisions about preimplantation genetic testing (PGT) or prenatal diagnosis.

For the rare homozygous individual, management is supportive and ideally coordinated by a specialized mitochondrial disease center. Treatments under investigation in animal models include rapamycin (mTOR inhibition to reduce cellular energy demand) and ketogenic diet (providing an alternative fuel source that bypasses the complex I block). Microglial ablation has extended lifespan in mouse models by reducing neuroinflammation. None of these are established clinical protocols, but referral to a mitochondrial disease specialist ensures access to current evidence and any available clinical trials.

Interactions

As an autosomal recessive condition, the key interaction is the combination of two heterozygous NDUFS4 c.462delA carriers producing a homozygous child. This is documented as a Mendelian transmission pattern, not a genetic interaction in the complex-I-pathway sense. There are no documented gene-gene interactions between NDUFS4 c.462delA and other nuclear-encoded complex I subunit variants in terms of modifying carrier status — two heterozygous carriers of different NDUFS4 pathogenic alleles could produce a compound heterozygous affected child, which is biologically equivalent to homozygosity in terms of complex I loss.

Angiotensinogen (AGT) is the precursor protein of the renin-angiotensin system¹¹ renin-angiotensin system
The renin-angiotensin system (RAS) is a hormonal cascade that regulates blood pressure, fluid balance, and electrolyte homeostasis. Renin cleaves AGT to form angiotensin I, which ACE converts to angiotensin II — a potent vasoconstrictor (RAS), one of the body's primary blood pressure control mechanisms. The M235T variant (rs699) changes a methionine to threonine at position 235 of the mature protein, and is one of the most-studied cardiovascular genetic variants with over 300 epidemiological studies and at least 15 meta-analyses published since its discovery in 1992.

The Mechanism

The G allele (coding for threonine at position 235) is associated with 10-30% higher plasma angiotensinogen levels compared to the A allele (methionine). More angiotensinogen means more substrate for renin, leading to increased production of angiotensin II²² angiotensin II
A powerful vasoconstrictor hormone that raises blood pressure by narrowing blood vessels and stimulating aldosterone release, which causes sodium and water retention, the hormone that constricts blood vessels and promotes sodium retention.

The variant is in linkage disequilibrium with a promoter polymorphism (rs5051) that increases AGT gene transcription. Recent research using UK Biobank data suggests the M235T variant may also exert cell-type-specific effects on AGT expression, particularly in the kidney, where local angiotensin II production can independently influence blood pressure.

The Evidence

Blood pressure and hypertension: A meta-analysis of 39 studies³³ meta-analysis of 39 studies
Defined Yilmaz et al. M235T polymorphism in the angiotensinogen gene and cardiovascular disease: An updated meta-analysis. Anatol J Cardiol, 2019 with 9,225 cases and 8,406 controls found the T allele (G on plus strand) associated with cardiovascular disease risk overall (OR 1.16, allelic model). The effect was strongest in East Asian populations (OR 1.46) where the G allele is very common (83%), while Caucasian populations showed no significant association in isolation.

Sodium sensitivity: A large cross-sectional study⁴⁴ large cross-sectional study
Norat et al. Blood pressure and interactions between the angiotensin polymorphism AGT M235T and sodium intake. Am J Clin Nutr, 2008 of 11,384 participants demonstrated that the blood pressure effect of sodium intake approximately doubles in AG and GG carriers compared to AA homozygotes. Carriers of the G allele show the greatest blood pressure reduction when sodium intake is lowered. An earlier intervention trial⁵⁵ earlier intervention trial
Hunt et al. Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Hypertension, 1999 confirmed that T235 carriers (G allele) experience significantly greater systolic blood pressure reduction with modest salt restriction.

Exercise response: The HERITAGE Family Study⁶⁶ HERITAGE Family Study
Rankinen et al. AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study. Am J Physiol, 2000 followed 476 sedentary individuals through 20 weeks of endurance training. Men with AA or AG genotypes reduced diastolic blood pressure by 3-4 mmHg at submaximal exercise, while GG homozygotes showed virtually no blood pressure improvement (0.4 mmHg). This suggests GG carriers may need different training strategies to achieve cardiovascular benefits.

Athletic performance: A study of Polish athletes⁷⁷ study of Polish athletes
Zarebska et al. Association of rs699 (M235T) polymorphism in the AGT gene with power but not endurance athlete status. J Strength Cond Res, 2013 found the GG genotype (Thr/Thr) was 2.2 times more common in power athletes than controls and 3.1 times more common than in endurance athletes. The higher angiotensin II levels associated with the G allele may favour power and strength through effects on muscle growth, vasoconstriction, and cardiac hypertrophy.

Practical Implications

The M235T variant has its greatest practical impact through sodium sensitivity. If you carry one or two G alleles, reducing sodium intake to below 2,000 mg/day can meaningfully lower blood pressure. This is especially relevant given that average Western diets contain 3,400-4,000 mg of sodium daily.

For exercise, GG carriers may derive greater cardiovascular benefit from incorporating power and resistance training alongside aerobic exercise, rather than relying solely on endurance training for blood pressure management. Monitoring blood pressure regularly helps track whether your exercise programme and dietary choices are effective for your genotype.

Interactions

The AGT M235T variant interacts with the AGT promoter variant rs5051, which is in strong linkage disequilibrium. The T174M variant (rs4762) in the same gene can compound the effect on angiotensinogen levels. Additionally, an interaction with the ACE insertion/deletion polymorphism has been documented: the HERITAGE study found that GG homozygotes carrying the ACE D allele showed no blood pressure response to endurance training, while other genotype combinations benefited. Population context matters — the G allele frequency ranges from 41% in Europeans to 85% in Africans, so the clinical significance varies substantially across ancestries.

Vitamin E is the body's primary fat-soluble antioxidant¹¹ fat-soluble antioxidant
A molecule that protects cell membranes from oxidative damage by neutralizing lipid peroxyl radicals, protecting every cell membrane from oxidative damage. But absorbing vitamin E from food is only the first step --- your liver must actively select and redistribute it to the rest of your body. That job falls to a single protein: alpha-tocopherol transfer protein²² alpha-tocopherol transfer protein
A liver protein encoded by the TTPA gene that binds alpha-tocopherol and loads it onto VLDL particles for systemic distribution (alpha-TTP), encoded by the TTPA gene on chromosome 8.

The rs6994076 variant sits in the promoter region of TTPA, approximately 980 base pairs upstream of the gene's transcription start site. It determines how much alpha-TTP your liver produces, which in turn sets your baseline circulating vitamin E level and how effectively you respond to supplementation.

The Mechanism

Alpha-TTP is expressed primarily in the liver, where it binds alpha-tocopherol with high selectivity and loads it onto VLDL particles³³ VLDL particles
Very low-density lipoproteins --- the transport vehicles that carry fat-soluble vitamins and lipids from the liver to peripheral tissues for distribution throughout the body. Without this protein, dietary vitamin E would be rapidly excreted in bile rather than retained in circulation.

The T allele at position -980 creates a new binding site for the transcriptional repressor BCL6⁴⁴ BCL6
B-cell lymphoma 6 protein --- a zinc-finger transcription factor that suppresses target gene expression when bound to DNA. When BCL6 occupies this site, it suppresses TTPA promoter activity, reducing the amount of alpha-TTP protein produced. Less alpha-TTP means less efficient vitamin E retention and distribution.

Notably, TTPA expression is itself regulated by oxidative stress --- a feedback loop where the need for antioxidant protection upregulates the protein that delivers it. The -980T variant blunts this response, potentially limiting the body's ability to mobilize vitamin E during periods of increased oxidative demand.

The Evidence

The Wright et al. 2009 study⁵⁵ Wright et al. 2009 study
Wright ME et al. Association of variants in two vitamin E transport genes with circulating vitamin E concentrations and prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 2009 examined TTPA polymorphisms in 847 controls from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. The TT genotype had 3.1% lower baseline serum alpha-tocopherol compared to AA (p = 0.03). More strikingly, TT carriers showed a 25.4% lower serum response to three years of daily vitamin E supplementation (50 mg/day) compared to AA homozygotes (p = 0.002), with heterozygotes intermediate at 16.4% lower response (p = 0.005).

Ulatowski et al. 2012⁶⁶ Ulatowski et al. 2012
Ulatowski L et al. Expression of the alpha tocopherol transfer protein gene is regulated by oxidative stress and common single nucleotide polymorphisms. Free Radic Biol Med, 2012 confirmed the functional mechanism using luciferase reporter assays in human hepatocytes. The -980T variant significantly repressed promoter activity by creating a putative BCL6 binding site, providing a molecular explanation for the observed differences in vitamin E levels.

A Mediterranean cohort study⁷⁷ Mediterranean cohort study
Zanon-Moreno V et al. Effects of polymorphisms in vitamin E-, vitamin C-, and glutathione peroxidase-related genes on serum biomarkers and associations with glaucoma. Mol Vis, 2013 of 500 individuals independently confirmed the significant association between rs6994076 and plasma vitamin E levels (p < 0.001).

The T allele frequency varies substantially across populations: approximately 48% in Europeans, 73% in East Asians and Africans, and 70% in South Asians. This means TT homozygosity is far more common in non-European populations, where baseline vitamin E levels may be more often influenced by this variant.

Practical Implications

The effect of rs6994076 on baseline vitamin E is modest (~3%) but the impact on supplementation response is substantial (~25%). This has two practical consequences:

First, TT carriers may need higher doses of vitamin E supplements to achieve the same serum increase as AA carriers. Standard supplement doses may be less effective for them.

Second, the preferred form matters. Natural d-alpha-tocopherol⁸⁸ d-alpha-tocopherol
Also labeled as RRR-alpha-tocopherol; the naturally occurring stereoisomer that alpha-TTP binds most efficiently (RRR-alpha-tocopherol) is bound by alpha-TTP with far greater affinity than the synthetic dl-alpha-tocopherol mixture. When alpha-TTP availability is already reduced by the T allele, using the natural form maximizes what the protein can deliver.

Dietary sources of alpha-tocopherol include sunflower seeds, almonds, hazelnuts, wheat germ oil, and spinach. These provide vitamin E in its natural form and are the first-line approach to maintaining adequate levels regardless of genotype.

The AVED Connection

Loss-of-function mutations in TTPA cause the rare autosomal recessive disorder ataxia with vitamin E deficiency⁹⁹ ataxia with vitamin E deficiency
AVED (OMIM #277460) --- a progressive neurodegenerative condition caused by inability to retain dietary vitamin E, treatable with high-dose supplementation (AVED), characterized by progressive cerebellar ataxia and peripheral neuropathy. While rs6994076 is a common regulatory variant with mild effects --- not a disease-causing mutation --- it illustrates the same biological principle: alpha-TTP is the bottleneck for vitamin E retention, and any reduction in its function shifts circulating levels downward.

The body runs on two primary fuels: glucose and fat. During fasting, prolonged exercise, or illness, glucose runs low and the heart, liver, and muscles switch to burning fatty acids. This switch depends on mitochondrial beta-oxidation¹¹ mitochondrial beta-oxidation
A multi-step enzymatic cascade that strips two carbons at a time from fatty acid chains, generating acetyl-CoA and the electron carriers NADH and FADH2 that drive ATP production. Medium-chain acyl-CoA dehydrogenase (MCAD), encoded by ACADM, is the gatekeeper for fatty acids of 6–12 carbon chain length — the dominant fuel in fasting metabolism.

The c.985A>G variant (p.Lys329Glu) is the defining mutation of MCAD deficiency (MCADD)²² MCAD deficiency (MCADD)
The most common inborn error of fatty acid oxidation, with newborn screening incidence of ~1:10,000 in northern Europeans. It accounts for approximately 90% of all disease-causing ACADM alleles in people of European descent and reflects a single northwestern European founder event³³ northwestern European founder event
Gregersen et al. 1993 documented 100% haplotype association of G985 across 17 families from Belgium, Denmark, England, Ireland, Italy, and the Netherlands. Because MCADD is autosomal recessive, one copy (carrier state) is generally well-tolerated, but two copies cause complete or near-complete loss of MCAD activity — leaving the individual unable to process medium-chain fatty acids during metabolic stress.

The Mechanism

At position 329 in the MCAD protein, a lysine residue (positively charged) is replaced by glutamate (negatively charged). This charge reversal destabilizes the MCAD enzyme tetramer and impairs binding of the FAD cofactor essential for the acyl-CoA dehydrogenation reaction⁴⁴ acyl-CoA dehydrogenation reaction
The reaction that removes the first two hydrogens from a fatty acyl-CoA chain, initiating each cycle of beta-oxidation. The result is severe reduction in MCAD catalytic activity — and in homozygous individuals, virtual absence of the ability to oxidize C6–C12 fatty acids.

When MCAD is absent and the body is forced into fatty acid oxidation (fasting, fever, prolonged exercise), medium-chain acyl-CoA intermediates accumulate. These toxic intermediates interfere with the tricarboxylic acid cycle, disrupt gluconeogenesis (preventing the liver from generating glucose), and impair the urea cycle. The result is hypoglycemia, hyperammonemia, and energy failure — conditions that hit the heart hard. The myocardium is uniquely fatty-acid dependent, deriving 60–70% of its ATP from fat oxidation under normal conditions. When this pathway is blocked during demand, cardiac failure follows rapidly.

The Evidence

Cardiac involvement in MCADD is well-documented. Wiles et al. 2014⁵⁵ Wiles et al. 2014
First reported case of acquired prolonged QTc (517 ms) in MCADD — a neonate homozygous for c.985A>G whose ECG normalized within 41 days of metabolic stabilization established the arrhythmia connection. The QTc prolongation was attributed directly to the metabolic derangement — electrolyte imbalance and energy depletion in cardiac tissue — rather than a structural cardiac defect.

More dramatically, Morana et al. 2026⁶⁶ Morana et al. 2026
Novel tachycardiomyopathy presentation in a neonate homozygous for c.985A>C (p.Lys329Gln); complete recovery within 48 hours of IV glucose and carnitine — both p.Lys329 variants share the same functional consequence documented refractory supraventricular tachyarrhythmias, severe biventricular systolic dysfunction, and biventricular dilation in a neonate. Within 48 hours of disease-specific management (IV glucose, carnitine), cardiac function normalized completely — underscoring that these cardiac events are metabolic emergencies, not permanent structural disease.

Anderson et al. 2020⁷⁷ Anderson et al. 2020
Retrospective of 90 MCADD patients showing homozygous p.Lys329Glu carriers had C8-acylcarnitine of 23.4 ± 19.6 μmol/L; clinically diagnosed patients averaged 2.15 hypoglycemic events vs. 0.62 in screened cases quantified the biochemical severity: elevated C8-carnitine concentrations serve both as the diagnostic marker and the ongoing metabolic monitor. In a 66-patient Portuguese follow-up, Janeiro et al. 2019⁸⁸ Janeiro et al. 2019
Acute decompensations with cardiac failure and sudden cardiac death occurred even in newborn-screened patients, demonstrating that lifelong vigilance is required confirmed that newborn screening reduces but does not eliminate the risk of life-threatening events.

Everard et al. 2024⁹⁹ Everard et al. 2024
Belgian multi-center retrospective of 54 FAO disorder patients; MCADD was 75.9% of cases; acute crises produced cardiomegaly, arrhythmias, hepatomegaly, rhabdomyolysis provided the most recent multi-center confirmation of cardiac involvement, noting that triggers include prolonged fasting, intercurrent infections, and intense physical activity.

Population carrier rates reflect the northwestern European founder effect: approximately 1 in 68–101 individuals in the UK and Denmark, 1 in 84 in North Carolina Caucasians, and 1 in 333 in Italy Gregersen et al. 1993¹⁰¹⁰ Gregersen et al. 1993.

Practical Actions

For carriers (AG genotype), the key concern is the residual risk during extreme metabolic stress and — critically — the risk to offspring if a partner also carries the variant. For homozygous individuals (GG genotype), avoidance of fasting is non-negotiable. The GeneReviews MCADD chapter¹¹¹¹ GeneReviews MCADD chapter
Management authored by Chang, Lam, and Vockley at University of Washington; comprehensively updated through 2024 specifies: dietary fat capped at 30% of total energy, avoidance of medium-chain triglyceride-containing formulas and products, and age-appropriate fasting limits (2–3 hour feeds in infancy, overnight cornstarch in older children and adults).

Acylcarnitine monitoring via dried blood spot or plasma C8-acylcarnitine allows clinicians to detect metabolic stress before symptoms appear. Emergency protocols center on rapid IV glucose to suppress fatty acid mobilization — the metabolic equivalent of removing the trigger.

Interactions

Variants in complementary fatty acid oxidation genes — including ACADVL (very long chain ACAD), ACADS (short chain ACAD), and HADHA (long chain 3-hydroxyacyl-CoA dehydrogenase) — affect adjacent steps in the same beta-oxidation cascade. Compound heterozygosity between ACADM variants (e.g., c.985A>G on one allele and a rarer frameshift or nonsense ACADM variant on the other) is the second most common genetic configuration in MCADD and typically produces a phenotype similar to homozygous c.985A>G. Carnitine transporter variants (SLC22A5) can reduce carnitine availability, compounding the metabolic stress when MCAD activity is already impaired.

Your immune system's first line of defense against bacteria depends on sensing microbial invaders through a family of receptors called Toll-like receptors (TLRs). TIRAP (also known as MAL)¹¹ TIRAP (also known as MAL)
TIR domain-containing adaptor protein; bridges activated TLR2 and TLR4 receptors to the downstream signalling protein MyD88 is an essential adaptor molecule in this alarm system. The Ser180Leu variant (rs8177374) subtly alters the shape of TIRAP's TIR domain, changing how strongly it bridges the receptor to the signaling cascade. The result is one of genetics' clearest illustrations of balancing selection²² balancing selection
evolutionary pressure that maintains two alleles because each is advantageous in different conditions or gene doses — carrying one copy of the leucine variant appears to tune innate immunity into an optimal protective state, while carrying two copies tips the balance in the opposite direction.

The Mechanism

When bacteria invade, Gram-negative bacterial lipopolysaccharide (LPS) activates TLR4, while Gram-positive bacterial lipoproteins activate TLR2³³ Gram-negative bacterial lipopolysaccharide (LPS) activates TLR4, while Gram-positive bacterial lipoproteins activate TLR2
These are the two major innate immune receptors for bacterial threats. Both receptors recruit TIRAP to bridge them to MyD88, which then activates NF-κB and triggers production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-8.

Serine 180 sits in a surface-exposed cavity of the TIRAP TIR domain. The S180L substitution replaces a small polar amino acid with a bulky hydrophobic leucine⁴⁴ The S180L substitution replaces a small polar amino acid with a bulky hydrophobic leucine
This causes steric occlusion of the binding cavity, likely altering the geometry of receptor-adaptor interactions. The result is reduced efficiency of MyD88 recruitment and a modestly attenuated downstream signaling response. Crucially, this attenuation appears to affect signaling intensity rather than completely abolishing it — heterozygous carriers still mount effective immune responses, but with less inflammatory overshoot.

In homozygous carriers (TT), an unexpected paradox emerges: rather than simply further dampening the response, structural modelling suggests the altered protein-protein geometry leads to an abnormal signaling configuration, and clinical studies found that TIRAP 180L homozygous patients with Gram-negative bacterial sepsis showed a paradoxical cytokine overshoot⁵⁵ clinical studies found that TIRAP 180L homozygous patients with Gram-negative bacterial sepsis showed a paradoxical cytokine overshoot
Significantly more severe infection and decreased tissue oxygenation compared with CC and CT genotypes.

The Evidence

The landmark study came from Khor et al. in Nature Genetics 2007⁶⁶ Khor et al. in Nature Genetics 2007
Case-control study of 6,106 individuals from Gambia, Kenya, United Kingdom, and Vietnam, screening 33 TLR pathway SNPs against four serious bacterial infectious diseases. TIRAP Ser180Leu heterozygosity was the standout finding, independently protecting against all four conditions studied: invasive pneumococcal disease (OR 0.59, P=0.003), bacteremia (OR 0.40, P=0.003), malaria (OR 0.47, P=0.002), and tuberculosis (OR 0.23, P=0.008). The combined p-value across all diseases was 9.6 × 10⁻⁸ — well beyond genome-wide significance — and the protective effect was seen in both African and European populations.

A 2009 PNAS study⁷⁷ A 2009 PNAS study
Functional and genetic analysis in German patients with Gram-negative bacterial sepsis extended these findings and provided the evolutionary context: the T allele appears to have been positively selected because heterozygosity confers an advantage against the most common bacterial killers, but homozygosity creates a vulnerability. This balanced polymorphism pattern — where the heterozygous state is optimal — explains why the variant persists at 10–13% frequency in European populations rather than sweeping to fixation.

Multiple independent studies have confirmed the protective role of S180L heterozygosity in tuberculosis specifically. Multiple replication cohorts across populations confirmed the protective association, and research from Colombia confirming protection against TB and SLE⁸⁸ research from Colombia confirming protection against TB and SLE
Castiblanco et al. 2008, OR 0.53 for TB, OR 0.29 for SLE in 1,325 Colombian subjects broadly replicated the protection against tuberculosis.

The variant also shows intriguing autoimmune associations. A study of systemic lupus erythematosus (SLE) found the Leu180 allele reduced SLE risk by approximately 73%⁹⁹ A study of systemic lupus erythematosus (SLE) found the Leu180 allele reduced SLE risk by approximately 73%
Consistent with the idea that stronger innate immune activation contributes to autoimmune pathology. Conversely, TIRAP Ser180Leu was positively associated with Behcet's disease in UK patients¹⁰¹⁰ TIRAP Ser180Leu was positively associated with Behcet's disease in UK patients
A mucosal inflammatory disorder where increased cytokine production at lesion sites worsens disease persistence, illustrating that the T allele's effects depend on disease context.

Practical Implications

For heterozygous CT carriers, the data paint an encouraging picture: your innate immune system appears to be calibrated toward effective defense against common bacterial pathogens without excessive inflammatory collateral damage. This is not a license to ignore infection prevention, but it is a genuine genetic advantage for resisting a broad class of serious infections.

For homozygous TT carriers (approximately 3% of Europeans), the situation is more nuanced. The same variant that protects heterozygotes becomes a potential liability at the homozygous state — particularly in the context of severe Gram-negative bacterial infections or surgical sepsis. Standard vigilance around infection prevention and prompt treatment of bacterial infections is important.

The TIRAP pathway also interacts functionally with the TLR4 receptor variants already in this database (rs4986790 Asp299Gly and rs4986791 Thr399Ile). Both receptor and adaptor variants affect the same LPS-sensing cascade, and individuals carrying variants in both genes may show compounded modulation of innate immune responses.

Interactions

TIRAP Ser180Leu sits functionally downstream of rs4986790 (TLR4 Asp299Gly)¹¹¹¹ rs4986790 (TLR4 Asp299Gly) and rs4986791 (TLR4 Thr399Ile)¹²¹² rs4986791 (TLR4 Thr399Ile). Since TIRAP bridges TLR4 to MyD88, carrying functional variants in both TLR4 and TIRAP affects the same signaling cascade at two points. The TLR4 variants reduce receptor sensitivity to LPS; TIRAP Ser180Leu modulates how efficiently the activated receptor signal is propagated downstream. Combined variant carriers may show additive dampening of TLR4-mediated innate immune responses.

The MyD88 rs6853 variant is a related pathway partner — MyD88 is the downstream target that TIRAP recruits. Studies of pulmonary tuberculosis have examined both TIRAP rs8177374 and MyD88 rs6853 simultaneously, finding independent protective effects for both, suggesting these adaptor variants can combine to shape tuberculosis susceptibility through the same MyD88-dependent pathway.

SR-BI¹¹ SR-BI
Scavenger receptor class B type I; the primary hepatic receptor for selective cholesterol ester uptake from HDL particles sits at the end of the reverse cholesterol transport pathway — the arterial self-cleaning system that moves cholesterol from artery walls back to the liver. While most HDL-related genes work upstream, SR-BI is the final step: it docks HDL in the liver and extracts its cholesterol ester cargo, then sends the lipid-depleted particle back to scavenge more. When SR-BI runs less efficiently, that pipeline backs up — and the excess HDL sitting in circulation looks protective on a standard lipid panel but may not actually be doing its job.

The rs838880 variant sits in the 3' untranslated region (3'UTR) of SCARB1, a regulatory stretch of RNA that controls how much SR-BI protein is produced. It is one of the most replicated common variants at the SCARB1 locus and one of the original 95 lipid-influencing loci identified in the landmark 2010 Global Lipids GWAS²² 2010 Global Lipids GWAS
Teslovich et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010.

The Mechanism

The rs838880 T allele lies in a region of the SCARB1 3'UTR that may influence mRNA stability or translational efficiency — two key post- transcriptional mechanisms that determine how much SR-BI protein the liver actually produces from a given transcript. While the precise molecular mechanism has not been fully resolved for this specific variant, it tags a well-characterized haplotype associated with reduced hepatic SCARB1 expression ³³ Sex-specific regulation of SCARB1 expression in liver has been shown; gene variants interact with estrogen signalling to modulate SR-BI levels differently in men and women. Less SR-BI protein means slower selective uptake of cholesterol esters from HDL, resulting in marginally lower plasma HDL-C as measured in large population studies.

This is distinct from the dramatic paradox seen with rare loss-of-function missense mutations in SCARB1 (such as P297S), which cause pronounced hyperalphalipoproteinemia⁴⁴ pronounced hyperalphalipoproteinemia
Abnormally elevated HDL-C — the opposite of what most people consider a cardiovascular risk factor, yet associated with impaired cholesterol efflux and increased atherosclerosis in carriers of rare SR-BI mutations. At rs838880, the per-allele effect on plasma HDL-C is modest (~0.61 mg/dL per T allele), but the variant has been replicated at genome-wide significance in some of the largest lipid GWAS ever conducted.

The Evidence

The Global Lipids Genetics Consortium 2013 study⁵⁵ Global Lipids Genetics Consortium 2013 study
Willer et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013 — the largest lipid GWAS at the time, with over 188,000 individuals — confirmed rs838880 as a significant HDL-C locus (C allele beta +0.048 SD units, p=6×10⁻³²). The T allele decreases HDL-C. The effect is additive and consistent across European, East Asian, and African ancestries.

A 2022 study of nephrosclerosis patients⁶⁶ 2022 study of nephrosclerosis patients
González et al. Tag-SNPs in Phospholipase-Related Genes Modify the Susceptibility to Nephrosclerosis and its Associated Cardiovascular Risk. Frontiers in Pharmacology, 2022 found that rs838880 was associated with nephrosclerosis susceptibility (OR 1.48, 95% CI 1.11–1.96, p=0.007) in 1,209 patients, suggesting the variant's cardiovascular-metabolic effects extend to renal vasculature.

The per-allele effect on HDL-C is modest. However, meta-analyses of SCARB1 rs5888⁷⁷ meta-analyses of SCARB1 rs5888
Ye et al. Meta-analysis of the association between SCARB1 polymorphism and fasting blood lipid levels. Oncotarget, 2017 — a coding variant in strong linkage disequilibrium with rs838880 — show that SCARB1 T-allele haplotypes are associated with higher HDL-C and lower triglycerides in non-Asian men but not women, consistent with sex-specific regulation of hepatic SR-BI expression.

Practical Actions

For TT homozygotes, the combined effect of two T alleles produces the lowest SR-BI-mediated HDL processing of the three genotypes. The actionable focus is on supporting the reverse cholesterol transport pathway through non-SR-BI mechanisms: increasing cholesterol efflux via ABCA1/ABCG1 (promoted by regular physical activity and soluble fiber), and monitoring lipid particle quality rather than just HDL-C quantity. Monitoring HDL particle number and function (via direct apolipoprotein A-I measurement) is more informative than HDL-C alone when SR-BI expression may be reduced.

Saturated fat intake is particularly relevant: high dietary saturated fat raises LDL-C and suppresses HDL-C in genetically predisposed individuals. Reducing saturated fat below 7% of total energy and substituting unsaturated fats is a specific strategy supported by the cardiovascular risk context of reduced SR-BI activity.

Interactions

rs838880 sits in a region of strong linkage disequilibrium with other SCARB1 variants including rs5888 (a synonymous coding variant with independent functional evidence) and rs10846744 (an intronic variant associated with CHD in Chinese populations). These variants may tag the same underlying haplotype. The rs11057830 SCARB1 intronic variant (already in the GeneOps database) affects a different functional outcome — carotenoid and vitamin E absorption — highlighting that SCARB1 has multiple independent functional regions.

Users carrying both reduced SR-BI expression (rs838880 TT) and APOE E4 (rs429358 CT/CC) would be expected to face compounded cardiovascular risk from both impaired reverse cholesterol transport and elevated LDL-C.

The MRAS gene (Muscle RAS Oncogene Homolog) on chromosome 3q22.3 encodes a small GTPase¹¹ GTPase
a molecular switch protein that cycles between active (GTP-bound) and inactive (GDP-bound) states to relay signals inside cells belonging to the Ras superfamily. MRAS is highly expressed in cardiovascular tissue — particularly the heart and aorta — where it participates in MAPK/ERK and PI3K/AKT signaling²² MAPK/ERK and PI3K/AKT signaling
pathways that control cell growth, proliferation, migration, and survival in vascular smooth muscle cells. The rs9818870 variant, located in the 3' untranslated region of MRAS, was identified in 2009 as one of the earliest GWAS-confirmed susceptibility loci for coronary artery disease beyond the landmark 9p21 locus.

The Mechanism

rs9818870 sits in the 3' UTR of MRAS, in close proximity to a cluster of microRNA binding sites³³ microRNA binding sites
short sequences that let regulatory microRNA molecules bind to the mRNA and control how much protein is made. The T allele alters the local mRNA secondary structure at this region, disrupting miRNA binding and resulting in higher MRAS transcript levels in arterial and cardiac tissue. This eQTL effect — the T allele raising MRAS mRNA levels specifically in the aorta and heart — is the proposed causal mechanism by which the variant increases atherosclerosis susceptibility.

Elevated MRAS activity in vascular smooth muscle cells (VSMCs) promotes cell proliferation, migration, and phenotypic switching through MAPK/ERK signaling. These processes are central to atherosclerotic plaque formation: VSMCs that migrate into the intimal layer, proliferate, and change phenotype from contractile to synthetic contribute to plaque growth and destabilization. Additionally, single-cell coronary artery epigenomic studies identified that an intronic CAD susceptibility variant in high LD with rs9818870 (rs13324341) disrupts a MEF2-binding site⁴⁴ MEF2-binding site
myocyte enhancer factor 2, a transcription factor that regulates genes controlling VSMC response to atherosclerotic stimuli specifically in smooth muscle cells, providing further mechanistic support.

The Evidence

Erdmann et al. 2009⁵⁵ Erdmann et al. 2009
Three-stage GWAS in 19,407 cases and 21,366 controls of European ancestry identified rs9818870 on chromosome 3q22.3 as a robust CAD susceptibility locus with an odds ratio of 1.15 (95% CI: 1.11–1.19) and genome-wide significant p-value of 7.44 × 10⁻¹³ — a highly consistent signal replicated across four independent datasets. The T allele frequency was higher in cases (19.5%) than controls (15.0%) in the discovery cohort.

Subsequent studies confirmed the variant as a predictor of cardiovascular events in healthy individuals⁶⁶ predictor of cardiovascular events in healthy individuals
Genomic risk variants at 1p13.3, 1q41, and 3q22.3 associated with cardiovascular outcomes in CAD-free subjects, PMID 21984477 free of established coronary disease (p=0.045 in the healthy volunteer cohort). A Chinese study also found the TT homozygous genotype associated with significantly elevated atherosclerosis risk (p=0.041).

However, replication has been inconsistent across all populations. The Czech population study⁷⁷ The Czech population study
2,452 ACS patients (1,779 male, 673 female) and controls did not confirm the association with acute coronary syndrome (OR 1.05, 95% CI 0.89–1.24), and Pakistani cohorts similarly found no significant association. The T allele frequency is notably lower in East Asian (~3.5%) and African (~7%) populations compared to Europeans (~15%), limiting the power of non-European replication studies. The variant's effect appears strongest and most consistently demonstrated in populations of European ancestry.

The 2024 MRAS review confirms that CAD risk variants in this gene, including rs9818870, increase MRAS expression primarily in arterial and aortic tissue through eQTL effects, with the mechanism operating specifically through smooth muscle cell biology rather than lipid metabolism — making this risk pathway mechanistically distinct from traditional lipid-based cardiovascular risk.

Practical Actions

Because the rs9818870 mechanism operates through vascular smooth muscle cell biology and inflammatory signaling rather than lipid metabolism, the most relevant interventions target arterial health and cardiovascular risk factor management. For T allele carriers — particularly CT and TT — closer attention to cardiovascular biomarker monitoring is warranted, as the genetic risk operates independently of standard lipid levels.

Statin therapy remains the most evidence-based pharmacological intervention for modifiable cardiovascular risk reduction, and the pleiotropic (lipid-independent) effects of statins on vascular inflammation and smooth muscle cell function may be particularly relevant to the MRAS pathway. Monitoring high-sensitivity CRP alongside traditional lipid panels provides a fuller picture of vascular inflammatory risk.

Interactions

rs9818870 was identified in the same GWAS framework as rs1333049⁸⁸ rs1333049
9p21 locus, the strongest known CAD genetic risk factor, in CDKN2B-AS1. Both variants act through non-lipid mechanisms affecting vascular smooth muscle cell biology, and their effects on CAD risk are additive and independent of each other and of traditional risk factors. Carriers of risk alleles at multiple CAD loci (including 9p21 and 3q22.3) accumulate risk in a log-additive fashion; users with elevated risk at both loci should treat cardiovascular prevention as a high priority.

Deep inside chromosome 6 lies the major histocompatibility complex (MHC) — the most gene-dense region of the human genome and the strongest known genetic determinant of autoimmune disease. rs2040410 sits within this region, just downstream of the HLA-DQA1¹¹ HLA-DQA1
Human Leukocyte Antigen DQ alpha-1 chain gene. It acts as a tag marker: its T allele (reported as "A" in some older publications using the minus-strand convention) travels in near-perfect linkage with DRB1*0301, the allele that defines the DR3 branch of the highest-risk type 1 diabetes haplotype.

The Mechanism

HLA-DQ molecules are heterodimeric proteins assembled from an alpha chain (encoded by DQA1) and a beta chain (encoded by DQB1). Together they form a peptide-binding groove that presents antigens to CD4+ T cells. The specific shape of this groove — determined by which DQA1 and DQB1 alleles you carry — determines which peptides trigger immune responses and which are ignored.

The DR3 haplotype (DRB1*0301-DQA1*0501-DQB1*0201, also called DR3-DQ2) forms a groove with unusual binding properties: it presents a wide range of self-peptides and foreign antigens, but it also skews thymic selection of T cells in ways that increase susceptibility to autoimmune activation. HLA-DQ2²² HLA-DQ2
The DQ2 heterodimer is present in approximately 95% of celiac disease patients, and DQ2 homozygotes face a substantially higher risk than heterozygotes. The DR3-DQ2 haplotype is independently associated with type 1 diabetes, SLE, Sjögren's syndrome, and other conditions in which loss of tolerance to self-antigens is the central event.

rs2040410 itself is a non-coding downstream variant; it does not change any protein. Its value is as a proxy: the T allele captures the DR3 haplotype status from a standard SNP array, enabling high-throughput identification without the labour-intensive HLA typing³³ HLA typing
Traditional high-resolution HLA typing involves sequencing the DRB1, DQA1, and DQB1 loci directly — a process that costs ~$30 per sample versus ~$6 for SNP-based screening required for classical allele calling.

The Evidence

Barker et al. 2008⁴⁴ Barker et al. 2008
Barker JM et al. Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening. Diabetes 2008;57(11):3152-5. established rs2040410 as a tag for DRB1*0301 (R²=0.872) and showed that combining this SNP with rs7454108 (which tags DQB1*0302) identifies the DR3/4-DQ8 compound heterozygous genotype with 98.5% sensitivity and 99.7% specificity across 5,019 participants from the Type 1 Diabetes Genetics Consortium. In an independent DAISY cohort this rose to 100% sensitivity and specificity. The DR3/4-DQ8 genotype — marked by carrying both the T allele at rs2040410 and the C allele at rs7454108 — accounts for roughly 30–50% of childhood-onset type 1 diabetes cases in European populations.

Aly et al. 2006⁵⁵ Aly et al. 2006
Aly TA et al. Extreme genetic risk for type 1A diabetes. PNAS 2006;103(38):14074-9. followed siblings of type 1 diabetes probands who carried the DR3/4-DQ8 genotype and shared both HLA haplotypes with their affected sibling. Cumulative risk of islet autoimmunity reached 85% by age 15 — describing what the authors called "extreme genetic risk," three to four times higher than previously reported for any HLA configuration.

Beyond type 1 diabetes, the DR3 haplotype (and therefore the T allele at rs2040410) is consistently associated with systemic lupus erythematosus, Sjögren's syndrome, and sarcoidosis — conditions all involving dysregulated immune recognition of self-antigens through the DR3-DQ2 peptide-presentation axis.

Practical Actions

Carrying the T allele at rs2040410 does not mean you have or will develop type 1 diabetes or another autoimmune condition — DR3/4-DQ8 homozygotes in the general population have approximately 5% autoantibody prevalence by age 7. The risk is probabilistic and context-dependent. For carriers, the clinically actionable steps focus on monitoring for the earliest signs of autoimmune activation, since several conditions in the DR3-DQ2 risk constellation respond well to early intervention. Coeliac screening is particularly relevant because DQ2 (encoded by the DQA1*0501-DQB1*0201 alleles that travel with this haplotype) is a necessary precondition for gluten-triggered autoimmunity.

Interactions

rs2040410 (DR3 tag) and rs7454108 (DQ8 tag, DQB1*0302 proxy) are used together to identify the compound DR3/4-DQ8 genotype — the highest-risk type 1 diabetes HLA configuration. Individuals heterozygous for both markers (AG at rs7454108 and CT at rs2040410) merit the highest clinical vigilance. The interaction is not additive in a simple sense: the DR3/4-DQ8 combination confers significantly more risk than either the DR3 or DR4 haplotype alone, because the trans DQ heterodimer (DQA1*0301/DQB1*0201) is itself a high-affinity presenter of self-peptides.